As the biopharmaceutical industry advances more glycoproteins and biologics toward clinical trials, the need for flexible, high-precision glycosylation solutions has never been more critical. At Creative Biolabs, our end-to-end platform is designed to grow with your research, whether you're optimizing glycan synthesis, detecting subtle modifications, or unraveling complex structures. With cutting-edge analytics and decades of hands-on experience, we're not here to just solve problems—we're here to turn your glycoscience challenges into breakthroughs.
What Researchers Struggle With
Researchers often struggle with three major roadblocks:
-
Uncontrolled heterogeneity due to low-yield chemical synthesis and side reactions.
-
Poor compatibility with protein, making precise glycoengineering on biologics difficult.
-
Scale-up bottlenecks, where lab-level modifications fail in larger bioprocessing workflows.
How Creative Biolabs Solves It
To address these challenges, Creative Biolabs offers fully integrated solutions for chemical and enzymatic glycosylation:
-
Our enzymatic glycosylation platforms use highly specific glycosyltransferases and glycosidases to introduce uniform glycans at defined sites—especially useful for therapeutic antibodies at Asn297.
-
We combine chemoenzymatic strategies, leveraging the precision of enzymatic steps and the versatility of chemical coupling to synthesize complex glycan structures, including rare C-glycosides and branched sialylated glycans.
-
With host cell engineering, we reprogram CHO cells to produce human-compatible glycoforms with reduced immunogenicity and enhanced pharmacokinetics.
Example: PD-1 Antibody Optimization
A client developing a PD-1 monoclonal antibody faced inconsistent clinical responses due to batch variability. By applying our enzymatic core-fucose removal service, fucosylation levels were reduced by 10%, resulting in a measurable increase in ADCC activity and improved clinical performance in Phase III trials.
Challenges in Glycan Detection
Modern glycomics research is limited by:
-
Subtle modifications often escape detection, especially in complex matrices like serum or tumor interstitial fluid.
-
Real-time monitoring is limited, impeding optimization of bioreactor conditions.
-
Clinical translation requires high-throughput, yet specific platforms, which many laboratories lack.
Our Tailored Detection Solutions
Creative Biolabs provides high-sensitivity and multi-dimensional detection technologies:
-
Using high-resolution LC-MS-based glycopeptide profiling technologies, we can identify over 600 glycopeptides from a single serum or saliva sample.
-
Our electrochemical biosensors enable real-time monitoring of sialic acid fluctuations in bioreactors, helping clients optimize upstream parameters.
-
We offer lectin microarrays that allow rapid, parallel detection of multiple glycoforms with glycan-specific probes—ideal for disease biomarker screening.
Example: Saliva-Based HCC Biomarker Discovery
Analyzing saliva samples from liver cancer patients, we identified glycosylation shifts in ORM1/ORM2 proteins. Using our mass spectrometry and lectin array platform, we built a predictive model with high sensitivity for early HCC detection. For comprehensive detection, our lectin microarray and mass spectrometry platforms offer complementary glycan specificity and sensitivity.
Profiling Glycans: From Structure to Biological Function
Where Analysis Often Falls Short
-
High heterogeneity at each site makes it hard to distinguish biologically active glycoforms.
-
Lack of integrative analysis tools obscures pathway-level insights.
-
No clear path to clinical validation, making biomarker translation inefficient.
Our Full-Cycle Analytical Approach
Creative Biolabs enables functional interpretation and clinical correlation:
-
AI-assisted annotation tools efficiently resolve glycan compositions and calculate glycosylation mass shifts with higher throughput.
-
We integrate glycan data with interaction databases to identify regulatory roles of glycans in pathways such as ferroptosis, immune evasion, or PI3K-Akt signaling.
-
Our end-to-end support guides clients from biomarker discovery to assay development.
Example: PD-L1 Glycosylation in Lung Cancer
Using a combination of high-resolution MS and glycan microarrays, we found that sialylation of PD-L1 in patient saliva correlated with immune escape and non-responsiveness to PD-1 blockade. This novel marker is now under further development for stratified clinical trials. Learn more about our Glycan Profiling and Biomarker Discovery Services that convert raw data into actionable insights.
Glycosylation Analysis Technologies at Creative Biolabs
To meet the diverse analytical needs of glycoscience, Creative Biolabs offers an unmatched portfolio of advanced glycoprotein analysis platforms:
Why Partner with Creative Biolabs?
-
Comprehensive glycosylation service coverage—from glycan synthesis to high-throughput analysis
-
Access to the widest range of advanced analytical technologies under one roof
-
Expert scientific consultation and customizable workflows
-
Proven experience in clinical biomarker translation and biopharmaceutical support
Let Creative Biolabs be your trusted partner for glycosylation-focused projects. Whether you're characterizing glycosylation changes in disease, developing glycoengineered biologics, or validating diagnostic biomarkers—we bring the expertise, platforms, and passion to accelerate your success. Contact us today to discuss your project!
Reference
-
He, Mengyuan, Xiangxiang Zhou, and Xin Wang. "Glycosylation: mechanisms, biological functions and clinical implications." Signal Transduction and Targeted Therapy 9.1 (2024): 194. https://doi.org/10.1038/s41392-024-01886-1
Related Services
Resources
For Research Use Only.
Contact Us
Follow us on
